Allergy Therapeutics shows dose response in midphase trial, setting stage for pivotal program

A phase 2 trial of Allergy Therapeutics’ grass pollen candidate met its primary endpoint of showing a dose-response relationship. With the trial also establishing a recommended dose of the short course subcutaneous allergen-specific immunotherapy, Allergy is set to move into phase 3 next year.